Project Grant K08EB036081
Award Date
8/1/24
Completion Date
5/31/28
Dollars Obligated
$582K
Federal Agency
National Institute of Biomedical Imaging and Bioenginering
Federal Grant Program
93.286
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $670,147 federal Project Grant awarded by the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to improve the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies for cancer detection and management. The award to Vanderbilt University Medical Center aims to: Elucidate the role of the RNA binding protein SAM68 in mediating cell-free DNA (cfDNA) release from cells; Optimize pharmacologic approaches...
This $1,466,982 federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of novel genetic circuit engineering technologies for cellular diagnostic devices. The project aims to design recombinase-based digital enhancer circuits and self-assembled split recombinases to amplify input signals and improve the...
This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
This $440,287 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is funding the development of a simplified, accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The goal is to democratize cancer biobanking by enabling lower-resource institutes to conduct comprehensive molecular analyses on smaller tumor samples, including genomic sequencing, gene expression profiling, and protein...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...
This $230,010 Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports the development and application of a novel epigenome sequencing platform called Glycosylase-Implemented Epigenome Sequencing (GLIMP-SEQ). GLIMP-SEQ is designed to profile 5-methylcytosine (5mC) with high sensitivity and fidelity, enabling analysis of degraded clinical samples such as formalin-fixed, paraffin-embedded (FFPE) tissues and cell-free DNA (cfDNA). Specific objectives...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $646,186 to Nord Bio Inc. to develop and evaluate an assay to detect and monitor cell-free tumor DNA levels in saliva samples. The goal is to create a non-invasive method for early cancer detection and residual disease monitoring, focusing initially on head and neck squamous cell carcinoma. The project will utilize duplex sequencing, algorithms, and machine learning to...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $400,000 in funding to Electronic Biosciences, Inc. to develop a novel nanopore-based sequencing approach capable of accurately characterizing repetitive DNA sequences. The project aims to address limitations of current sequencing-by-synthesis methods in accurately sequencing genomic repeats, which are known to harbor variations associated...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...